Name | MM-102 |
Description | MM-102 (HMTase Inhibitor IX) is a potent inhibitor of WDR5/MLL interaction with IC50 of 2.4 nM and Ki of less than 1 nM in a WDR5 binding assay. MM-102 can also specifically inhibit cell growth and induce apoptosis in leukemia cells carrying MLL1 fusion protein. |
Cell Research | MV4;11, KOPN8, and K562 cells are cultured in RPMI 1640 medium (ATCC) supplemented with 10% fetal bovine serum and 100 U/L penicillin-streptomycin and incubated at 37 °C under 5% CO2. Cells are seeded into 12-well plates for suspension at a density of 5 × 105 per well (1 mL) and treated with either vehicle control (DMSO, 0.2%) or MM-102 for 7 days. The medium is changed every 2 days, and compounds are resupplied. The CellTiter-Glo Luminescent Cell Viability Assay kit is used following the manufacturer’s instruction. First, 100 μL of the assay reagent is added into each well, and the content is mixed for 2 min on an orbital shaker to induce cell lysis. After 10 min incubation at room temperature, the luminescence is read on a microplate reader. (Only for Reference) |
Kinase Assay | In Vitro Histone Methyltransferase (HMT) Assay: The HMT assay is performed in 50 mM HEPES pH 7.8, 100 mM NaCl, 1.0 mM EDTA, and 5% glycerol at 22 °C. Each reaction contains 1.5 μCi of the co-factor, 3H-S-adenosylmethionine. H3 10-residue peptide is used as the substrate at 50 μM. Compounds are added at concentrations ranging from 0.125 to 128 μM and incubated with the pre-assembled WDR5/RbBP5/ASH2L complex at a final concentration of 0.5 μM for each protein for 2–5 min. Reactions are initiated by addition of the MLL1 protein at a final concentration of 0.5 μM and allowed to proceed for 30 min before preparing scintillation counting. To count samples, reactions are spotted on separate squares of P81 filter paper and precipitated by submerging in freshly prepared 50 mM sodium bicarbonate buffer with pH 9.0. After washing and drying, samples are vortexed in Ultima Gold scintillation fluid and counted. As a negative control, assays are performed using 0.5 μM MLL1/WDR5/RbBP5/ASH2L complex assembled with the non-interacting mutant, WDR5D107A. |
In vitro | 方法:用 MM-102 (HMTase Inhibitor IX) (25,50μM)处理 MLL1-AF9 转导的小鼠细胞,然后用定量 RT-PCR (QRT-PCR) 进行基因表达分析。
结果:MM-102 以剂量依赖性方式降低 HoxA9 mRNA 的表达 MM-102 在 50 μM 时 Meis-1 表达明显下降 ,MM-102不影响管家基因GAPDH的表达。[1]
方法:用 20 μM MM-102(20 μM ,20小时) 预处理细胞 24 小时,然后用 500 μM SNP 孵育,约24小时后评估细胞凋亡活性。
结果:SNP显着刺激软骨细胞凋亡,而用MM-102预处理的细胞减轻了SNP刺激软骨细胞凋亡,MM-102预处理有效挽救了FSS对软骨细胞的负面影响,这可能为基于表观遗传学的OA治疗奠定基础。[2] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 93 mg/mL (138.8 mM) H2O : 92 mg/mL (137.4 mM) Ethanol : 93 mg/mL (138.8 mM)
|
Keywords | MM 102 | Inhibitor | MM-102 | inhibit | Histone Methyltransferase |
Inhibitors Related | Tazemetostat hydrobromide | XY1 | BML-278 | MRTX-1719 | MAK683 | GSK126 | Tazemetostat | EPZ015666 | UNC 0631 | AMI-1 free acid | MS37452 | Piribedil |
Related Compound Libraries | Inhibitor Library | Bioactive Compound Library | Bioactive Compounds Library Max | Histone Modification Compound Library | Epigenetics Compound Library | PPI Inhibitor Library |